Patient-level | |||||||
---|---|---|---|---|---|---|---|
Treatment strategy | Added costs for a novel or group 5 intervention (€) | Cost of BR treatment | Hospitalization costs (€) | Outpatient care (€) | Monitoring costs (€) | Adverse event costs of group 5 drugs (€) | Total (€) |
Bedaquiline plus BR | 30,799 | 28,652 | 24,038 | 98 | 1970 | 17 | 85,575 |
Delamanid plus BR | 22,829 | 29,626 | 26,362 | 108 | 2152 | 2 | 81,079 |
Linezolid plus BR | 20,302 | 29,968 | 27,392 | 107 | 2569 | 121 | 80,460 |
BR only | 0 | 30,270 | 28,180 | 119 | 2393 | – | 60,962 |
Population-level, 100 patients with MDR-TB | |||||||
Bedaquiline plus BR | 3,079,915 | 2,865,240 | 2,403,791 | 9833 | 197,014 | 1735 | 8,557,529 |
Delamanid plus BR | 2,282,920 | 2,962,563 | 2,636,180 | 10,755 | 215,241 | 229 | 8,107,888 |
Linezolid plus BR | 2,030,217 | 2,996,842 | 2,739,250 | 10,715 | 256,867 | 12,091 | 8,045,981 |
BR only | 0 | 3,026,959 | 2,817,995 | 11,919 | 239,279 | – | 6,096,152 |